Cargando…

Efficacy and safety comparison between Lenvatinib and Sorafenib in hepatocellular carcinoma treatment: a systematic review and meta-analysis of real-world study

OBJECTIVE: Our study aimed to evaluate the efficacy and safety of Lenvatinib compared with Sorafenib for treating hepatocellular carcinoma (HCC) patients under real-world setting. METHODS: We retrieved relevant literature through the PubMed, Embase, Web of Science, and Cochrane Library databases fro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hua, Xuefeng, Yin, Ziwei, Liang, Jin, Chen, Wenbin, Gong, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams And Wilkins 2023
Materias:	Original Articles: Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695342/ https://www.ncbi.nlm.nih.gov/pubmed/37942731 http://dx.doi.org/10.1097/MEG.0000000000002668

Ejemplares similares

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
por: Chen, Yen-Yang, et al.
Publicado: (2020)

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
por: Kudo, Masatoshi, et al.
Publicado: (2020)

Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis
por: Luo, Jia, et al.
Publicado: (2022)

Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population
por: Lee, Shou-Wu, et al.
Publicado: (2022)

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study
por: Welzel, Tania M, et al.
Publicado: (2017)

Systematic review and meta-analysis: real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia
por: Wei, Bin, et al.
Publicado: (2018)

Efficacy and safety of lenvatinib–transcatheter arterial chemoembolisation sequential therapy followed by surgical resection for intermediate-stage hepatocellular carcinoma beyond Up-to-7 criteria: a study protocol for a multicentre, single-arm, prospective study
por: Oshita, Ko, et al.
Publicado: (2023)

Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
por: Chiang, Hsueh-Chien, et al.
Publicado: (2023)

Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Sorafenib Versus Lenvatinib-Based Sequential Systemic Therapy for Advanced Hepatocellular Carcinoma: A Real-World Analysis
por: Leyh, Catherine, et al.
Publicado: (2022)

Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study
por: Chen, Bowen, et al.
Publicado: (2022)

Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial
por: Pinyol, Roser, et al.
Publicado: (2019)

Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
por: Kim, Soo Young, et al.
Publicado: (2019)

Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis
por: Tran, Sally Ann, et al.
Publicado: (2018)

Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China
por: Zhu, Yun, et al.
Publicado: (2021)

Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy
por: Burgio, Valentina, et al.
Publicado: (2021)

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C
por: Colombo, M, et al.
Publicado: (2014)

Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China
por: Wang, Dong-Xu, et al.
Publicado: (2020)

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
por: Welzel, Tania M, et al.
Publicado: (2016)

Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells
por: Shi, Tingting, et al.
Publicado: (2021)

STK33 promotes hepatocellular carcinoma through binding to c-Myc
por: Yang, Tian, et al.
Publicado: (2016)

Safety and Efficacy of Sorafenib and Lenvatinib in Patients Who Underwent Surgery or Whole-Brain Radiotherapy for Brain Metastasis of Hepatocellular Carcinoma
por: Perng, Pang-Shuo, et al.
Publicado: (2022)

PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma
por: Lu, Li-Gong, et al.
Publicado: (2022)

Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis
por: Lee, Sung Won, et al.
Publicado: (2020)

Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
por: Zhao, Shu, et al.
Publicado: (2022)

Comparative study between sorafenib and lenvatinib as the first‐line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real‐world setting
por: Fukushima, Taito, et al.
Publicado: (2021)

Liver transplantation for hepatocellular carcinoma beyond the Milan criteria
por: Xu, Xiao, et al.
Publicado: (2016)

Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma
por: Shang, Runze, et al.
Publicado: (2021)

Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real‐world setting
por: Sho, Takuya, et al.
Publicado: (2019)

Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma
por: Chew, Valerie, et al.
Publicado: (2019)

Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma
por: Sasaki, Ryu, et al.
Publicado: (2022)

Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas
por: Amaddeo, Giuliana, et al.
Publicado: (2015)

Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma
por: Jühling, Frank, et al.
Publicado: (2021)

Efficacy and safety of acupuncture as an adjuvant treatment for acute pancreatitis: a protocol of systematic review and meta-analysis
por: Zhang, Kai, et al.
Publicado: (2019)

Keratin 19: a key role player in the invasion of human hepatocellular carcinomas
por: Govaere, Olivier, et al.
Publicado: (2014)

Tonicity-responsive enhancer-binding protein promotes hepatocellular carcinogenesis, recurrence and metastasis
por: Lee, Jun Ho, et al.
Publicado: (2019)

Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World
por: Li, Xiaowei, et al.
Publicado: (2022)

Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience
por: Wu, Wen-Chi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lui1t94kodhc8c60fd9gr7ab4q